Earnings release
Page 1
FINANCIAL RESULTS for the first nine months of 2026 05/11/2026 Laboratorios Farmacéuticos Rovi, S.A. ("ROVI", the "Company" or the "Group") and Subsidiaries - Investor Relations
Page 2
KEY FIGURES Summary IN € MILLIONS 9M 2026 9M 2025 Growth % Growth Operating revenue(1) 610.2 525.1 85.1 16 % Gross profit(2) 443.7 352.1 91.6 26 % EBITDA(3) 226.6 149.5 77.2 52 % EBIT(4) 198.7 127.3 71.5 56 % Net profit(5) 162.8 97.7 65.1 67 % Purchases of property, plant and equipment and intangible assets ("Capex") 50.3 38.5 11.9 31 % FCF(6) 61.9 63.3 (1.5) -2 % Gross profit as % of operating revenue 72.7 % 67.1 % 5.7 pp EBITDA as % of operating revenue 37.1 % 28.5 % 8.7 pp EBIT as % of operating revenue 32.6 % 24.2 % 8.3 pp Net profit as % of operating revenue 26.7 % 18.6 % 8.1 pp Capex as % of operating revenue 8.2 % 7.3 % 0.9 pp FCF as % of operating revenue 10.1 % 12.1 % -1.9 pp IN € MILLIONS As of Sept 30, 2026 As of Dec 31, 2025 Growth % Growth Net debt (-)/cash (+)(7) (27.9) (21.9) (6.0) 27% Note: certain numerical figures included in this document have been rounded. Therefore, discrepancies in tables between totals and the sums of the amounts listed may occur due to such rounding. (1) Operating revenue refers to revenue. (2) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used. (3) EBITDA calculated as profit before interest, taxes, depreciation and amortization. (4) EBIT calculated as profit before taxes and interest. (5) Net profit refers to profit for the period. (6) Free Cash Flow (FCF) calculated as net cash generated from operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment plus interest received. (7) Net debt (-)/cash (+) composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt. The consolidated financial statements of Group ROVI for the first nine months of 2026 and the comparative information for 2025 (balance sheet) and for the first nine months of 2025 (consolidated income statement and cash flow statement) are attached to this report (see Appendix 1). The figures for the first nine months of 2026 and the first nine months of 2025 are unaudited figures. Likewise, the figures as of December 31, 2025 are audited figures. 1
Page 3
CONTENTS HIGHLIGHTS FIRST NINE MONTHS OF 2026 ........................................................................ 3 MANAGEMENT REPORT .............................................................................................................. 7 INCOME STATEMENT ................................................................................................................. 7 REVENUES ...................................................................................................................................... 7 SPECIALTY PHARMACEUTICAL BUSINESS ........................................................................ 9 LOW MOLECULAR WEIGHT HEPARINS .............................................................................. 10 OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS .............................. 11 CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS ............................................ 11 CDMO BUSINESS ......................................................................................................................... 12 OTHER INCOME .......................................................................................................................... 12 COSTS .................................................................................................................................................. 12 GROSS PROFIT .............................................................................................................................. 12 RESEARCH AND DEVELOPMENT EXPENSES ................................................................... 13 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES ................................................ 13 DEPRECIATION ............................................................................................................................. 14 NET FINANCE RESULT .............................................................................................................. 14 EFFECTIVE TAX RATE ................................................................................................................. 14 FINANCIAL PERFORMANCE ....................................................................................................... 15 DIVIDEND ........................................................................................................................................... 17 FINANCIAL POSITION ................................................................................................................... 18 LIQUIDITY ........................................................................................................................................... 20 R&D UPDATE .................................................................................................................................... 24 ESG ....................................................................................................................................................... 25 APPENDIX 1 ....................................................................................................................................... 28 APPENDIX 2 ...................................................................................................................................... 32 2
Page 4
HIGHLIGHTS 9M 2026 ROVI REPORTED TOTAL REVENUE GROWTH OF 19% AND GROSS MARGIN EXPANSION OF 5.7 PERCENTAGE POINTS • Total revenue amounted to 633.7 million euros in the first nine months of 2026, up 19% compared to 534.1 million euros in the same period of 2025. • Operating revenue reached 610.2 million euros, representing year-on-year growth of 16%, mainly driven by the strong performance of the contract development and manufacturing business ("CDMO"), whose sales increased by 45% to 263.9 million euros in the first nine months of 2026. • Okedi® (Risperidone ISM®) continued to post strong growth, reaching sales of 53.0 million euros in the first nine months of 2026, up 29% compared with the same period of 2025. Sales in the third quarter of 2026 increased 35% compared with the third quarter of 2025 and 13% compared with the second quarter of 2026. • Sales of the heparin franchise (which includes low-molecular-weight heparins (LMWH) and other heparins) decreased by 5% to 180.9 million euros in the first nine months of 2026. This decrease was mainly attributable to lower international sales of both the enoxaparin biosimilar and bemiparin, as a result of high inventory levels held by partners. • Gross profit increased by 26% to 443.7 million euros, while gross margin expanded by 5.7 percentage points year-on-year to 72.7%. This improvement was positively impacted by the strong performance of the CDMO business, the growing contribution from Okedi®, lower LMWH raw material prices and the recognition of revenue associated with the R&D aid awarded by the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) for the LAISOLID project, which is recorded under the "Other income" line. • On 1 April 2026, ROVI announced the completion of the acquisition, through its subsidiary ROIS Phoenix Inc., of a pharmaceutical manufacturing plant located in Phoenix, Arizona (United States), together with a series of related assets and liabilities, under the Asset Purchase Agreement signed with Bristol Myers Squibb. The purchase price allocation (PPA) for the acquisition resulted in a bargain purchase gain, or "badwill," of 62.4 million euros. This was recognised as non-recurring income in the Group's consolidated income statement. • EBITDA increased by 52% to 226.6 million euros in the first nine months of 2026, with an EBITDA margin of 37.1%, up 8.7 percentage points compared to the same period of 2025. Excluding the impact of the badwill, EBITDA increased by 10% to 164.3 million euros, reflecting an EBITDA margin of 26.9%. • Net profit increased by 67% to 162.8 million euros in the first nine months of 2026. 3
Page 5
• The ROVI General Shareholders Meeting, held on 17 June 2026, approved the payment of a gross dividend of 0.9594 euros per share, representing approximately 35% of the consolidated net profit for 2025 attributable to the parent company. This dividend was paid on 15 July 2026. REVENUE BY REGION (%) REVENUE BY BUSINESS UNIT (€Mn) 36% 64% Spain International OUTLOOK In light of the strong performance delivered during the first nine months of 2026 and the visibility for the remainder of the year, ROVI upgrades its 2026 operating revenue guidance. The Company now expects operating revenue to increase by a mid-to high-single-digit percentage compared with 2025 , versus its previous guidance of growth in the low- to mid-single-digit range. This upgrade is mainly the result of the stronger expected growth of the CDMO business, as well as a favourable evolution of the LMWH business, driven by higher expected volumes from bemiparin partners. In line with common market practice, and with the aim of (i) starting from a more reliable full-year basis with integrated and coordinated forecasts, (ii) incorporating relevant year-end commercial and regulatory information, and (iii) reducing the degree of uncertainty surrounding the assumptions or factors that may affect the outlook, ROVI will publish its 2027 outlook in the presentation of its full-year 2026 results, scheduled for February 2027. 4 346.1 263.9 0.1 Specialty pharmaceutical business CDMO business Other operating revenue
Page 6
GAIN ON BARGAIN PURCHASE ARISING FROM THE ACQUISITION OF A MANUFACTURING FACILITY IN PHOENIX, ARIZONA On 1 April 2026, ROVI announced the completion of the Asset Purchase Agreement signed between its subsidiary ROIS Phoenix Inc. ("ROIS Phoenix") and Bristol Myers Squibb (“BMS”) for the acquisition of a pharmaceutical manufacturing facility in Phoenix, Arizona (United States), together with a number of related assets and liabilities. Completion of this purchase agreement took place after the customary closing conditions for transactions of this nature had been satisfied and in the absence of any significant adverse change since the agreement was signed. Simultaneously, Rovi Pharma Industrial Services, S.A.U., the parent company of ROIS Phoenix, and BMS entered into a Toll Manufacturing Agreement, with an initial term of five years, that sets out the conditions under which ROIS Phoenix will continue to manufacture for BMS at the facility. As a result of the purchase price allocation process for the Arizona facility, a bargain purchase gain of 62.4 million euros was recognised and booked as non-recurring revenue in ROVI's consolidated income statement. Likewise, when accounting for business combinations, there is a 12-month measurement period in which to evaluate the facts and circumstances existing at the acquisition date and, therefore, the measurement presented as of 30 September 2026 is considered provisional. 5
Page 7
Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: "During the first nine months of 2026, we continued to make progress in the execution of our growth strategy. Our CDMO division further strengthened its positioning through the integration of the Phoenix injectable manufacturing facility (Arizona, U.S.). At the same time, we continued to enhance this division by expanding capacity and incorporating new higher value-added services, such as the assembly of advanced drug delivery devices, including pre-filled pens and autoinjectors, in a market environment that continues to show strong demand for highly complex injectable solutions. We also continued to diversify our customer portfolio, which enhances the future visibility of the business and strengthens the resilience of our CDMO platform. Innovation remains one of ROVI’s key growth drivers. The growth of Risperidone ISM® and the progress achieved across our pipeline reinforce our confidence in the potential of the ISM® technology platform. In this regard, we continue to advance the development of Letrozole SIE, a quarterly injectable formulation for the treatment of hormone-dependent breast cancer, and Risperidone QUAR, a quarterly formulation for the treatment of schizophrenia, both of which have the potential to improve treatment adherence and clinical efficacy. At the same time, we remain committed to our low molecular weight heparin business, where we continue to advance initiatives aimed at improving operational efficiency, strengthening vertical integration and enhancing the long-term competitiveness of this franchise. The progress achieved during the year reinforces our confidence in ROVI’s growth prospects. The combination of a strong industrial platform, an increasingly diversified customer base, a growing international presence and a firm commitment to innovation enables us to look to the future with confidence and positions us favourably to deliver sustainab le growth and create long-term value for our shareholders and other stakeholders " 6
Page 8
MANAGEMENT REPORT for the nine-month period ending September 30th, 2026 INCOME STATEMENT IN € MILLIONS 9M 2026 9M 2025 Growth % Growth Operating revenue(1) 610.2 525.1 85.1 16 % Other income(2) 23.6 9.0 14.5 n.a. Total revenue(3) 633.7 534.1 99.6 19 % Cost of goods sold(4) (190.0) (182.0) (8.0) 4 % Gross profit(5) 443.7 352.1 91.6 26 % % margin(11) 72.7 % 67.1 % 5.7 pp R&D expenses(6) (58.4) (24.7) (33.7) 136 % SG&A(7) (221.2) (177.9) (43.3) 24 % Gain on bargain purchase 62.4 — 62.4 n.a. Share of profit in associates and joint ventures 0.1 0.0 0.1 n.a. EBITDA(8) 226.6 149.5 77.2 52 % % margin(11) 37.1 % 28.5 % 8.7 pp EBIT(9) 198.7 127.3 71.5 56 % % margin(11) 32.6 % 24.2 % 8.3 pp Finance Income/(Costs) (1.9) (1.9) 0.0 -1 % Profit before income tax 196.8 125.3 71.5 57 % Income tax (34.1) (27.6) (6.4) 23 % Effective tax rate 17.3 % 22.0 % -4.7 pp Net profit(10) 162.8 97.7 65.1 67 % Net profit attributable to parent company 162.9 97.8 65.1 67 % Profit attributable to minority interests (0.1) (0.1) (0.1) n.a. (1) Operating revenue refers to revenue. (2) Other income includes the recognition of government grants on non-financial non-current assets and other. (3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other. (4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use. (5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used. (6) R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development. (7) SG&A calculated as the amount of e mployee benefit expenses plus other operating expenses minus work carried out by the Group on non-current assets minus research & development expenses. (8) EBITDA calculated as profit before interest, taxes, depreciation and amortization. (9) EBIT calculated as profit before taxes and interest. (10) Net profit refers to profit for the period. (11)The gross margin and the EBITDA and EBIT margins are calculated as the result of dividing the gross profit, the EBITDA and the EBIT, respectively, by revenue, expressed as a percentage. 7
Page 9
REVENUES Total revenue by business unit IN € MILLIONS 9M 2026 9M 2025 Growth % Growth Specialty pharmaceutical business 346.1 343.3 2.8 1 % CDMO business 263.9 181.7 82.2 45 % Other operating revenue(*) 0.1 0.1 0.0 65 % Operating revenue(1) 610.2 525.1 85.1 16 % Other income(2) 23.6 9.0 14.5 n.a. Total revenue(3) 633.7 534.1 99.6 19 % (*) "Other operating revenue” includes service activities that are not material to the Group. In the nine-month 2025 results release, this amount was included within the “Contrast agents and other hospital products” line. (1) Operating revenue refers to revenue excluding the recognition of government grants on non-financial non-current assets and other. (2) Other income includes the recognition of government grants on non-financial non-current assets and other. (3) Total revenue calculated as operating revenue plus the recognition of government grants on non-financial non-current assets and other. Total revenue in the first nine months of 2026 amounted to 633.7 million euros, up 19% compared to 534.1 million euros in the same period of 2025. Operating revenue in the first nine months of 2026 was 610.2 million euros, up 16% compared to 525.1 million euros in the first nine months of 2025, mainly driven by the strong performance of the contract development and manufacturing business ("CDMO"), whose sales increased by 45% to 263.9 million euros in the first nine months of 2026. Sales outside Spain increased 25% in the first nine months of 2026, compared to the same period of 2025, to 393.0 million euros, mainly driven by the strong performance of the CDMO business, including the contribution from the Phoenix facility (USA). International sales represented 64% of operating revenue in the first nine months of 2026 compared to 60% in the first nine months of 2025. 8
Page 10
SPECIALTY PHARMACEUTICAL BUSINESS Sales of the specialty pharmaceutical business IN € MILLIONS 9M 2026 9M 2025 Growth % Growth Prescription-based pharmaceutical products 297.6 299.3 (1.7) -1 % LMWH franchise 173.7 183.6 (9.9) -5 % Enoxaparin biosimilar 107.0 112.8 (5.8) -5 % Bemiparin (Hibor) 66.7 70.8 (4.1) -6 % Sales in Spain 40.3 42.1 (1.8) -4 % International sales 26.4 28.7 (2.3) -8 % Okedi 53.0 41.0 12.0 29 % Neparvis 43.3 42.1 1.2 3% Volutsa 6.4 6.8 (0.4) -5 % Orvatez 7.1 10.6 (3.5) -33% Other products 22.7 24.0 (1.2) -5% Discounts to the National Health System (8.7) (8.7) 0.0 -0.1 % Contrast agents and other hospital products 47.8 43.3 4.4 10 % Other products 0.8 0.7 0.1 18 % Total specialty pharmaceutical business 346.1 343.3 2.8 1 % Sales of prescription-based pharmaceutical products decreased by 1% to 297.6 million euros in the first nine months of 2026. Sales of the heparin franchise (Low Molecular Weight Heparins and other heparins) decreased 5% to 180.9 million euros in the first nine months of 2026. Heparin sales represented 30% of operating revenue in the first nine months of 2026 compared to 36% in the first nine months of 2025. 9
Page 11
Heparin franchise IN € MILLIONS 9M 2026 9M 2025 Growth % Growth LMWH franchise 173.7 183.6 (9.9) -5 % Enoxaparin biosimilar 107.0 112.8 (5.8) -5 % Bemiparin (Hibor) 66.7 70.8 (4.1) -6 % Sales in Spain 40.3 42.1 (1.8) -4 % International sales 26.4 28.7 (2.3) -8 % Other heparins1 7.2 6.3 0.9 15 % Heparins franchise 180.9 189.8 (8.9) -5 % LOW MOLECULAR WEIGHT HEPARINS Sales of Low Molecular Weight Heparins (LMWH) (enoxaparin biosimilar and bemiparin) decreased 5% to 173.7 million euros in the first nine months of 2026. This decrease was mainly attributable to lower international sales of both the enoxaparin biosimilar and bemiparin, as a result of high inventory levels held by partners. ROVI maintains its expectation that LMWH sales will decrease by a mid-single-digit percentage in 2026. While inventory adjustments at partners and competitive pricing pressure continue to affect performance, the year-to-date evolution of the LMWH business has been more favourable than expected at the beginning of 2026. Enoxaparin biosimilar 31.8 43.6 40.6 39.2 33.0 44.9 41.2 37.4 28.5 Bemiparin (Hibor) 23.9 25.3 27.1 24.3 19.3 29.6 17.7 29.0 19.9 Sales in Spain 13.5 14.6 14.4 14.1 13.5 14.7 14.3 13.3 12.7 Intl. sales 10.4 10.7 12.7 10.2 5.8 14.8 3.5 15.7 7.2 Total LMWH sales 55.7 69.0 67.7 63.6 52.3 74.5 58.9 66.4 48.4 IN € MILLIONS Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Sales of the enoxaparin biosimilar decreased by 5% year-on-year to 107.0 million euros in the first nine months of 2026. Bemiparin sales decreased by 6% to 66.7 million euros in the first nine months of 2026 compared with the same period of 2025 . This performance was mainly driven by lower international sales, which fell by 8% to 26.4 million euros, primarily due to the high inventory levels held by international partners during the first nine months of 2026. Sales in Spain (Hibor®) decreased by 4% to 40.3 million euros, primarily due to lower penetration in the prophylaxis segment. Despite the year-on-year decline, ROVI expects bemiparin sales to be stronger in the fourth quarter, driven by the year-end 10 1 Other heparins are reported in the “Contrast agents and other hospital products” line.
Page 12
concentration of international orders. For 2026, ROVI continues to expect bemiparin sales to increase by a low single-digit percentage compared with 2025. OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS Sales of Okedi®, the first ROVI product based on its leading-edge drug delivery technology, ISM®, and indicated for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, reached 53.0 million euros in the first nine months of 2026, up 29% versus the first nine months of 2025. Sales in the third quarter of 2026 increased 35% compared with the third quarter of 2025 and 13% compared with the second quarter of 2026. During the first nine months of 2026, t he product was marketed in Germany, UK, Spain, Portugal, Italy, Austria, Greece, Serbia, the Nordic countries, Australia, Taiwan and the Netherlands. Looking ahead to the fourth quarter of 2026, Okedi® sales in Germany are expected to be impacted by its inclusion in the German pharmaceutical reference pricing system (Festbeträge), effective from October 1, 2026. This system groups therapeutically comparable medicines and establishes a maximum reimbursement level. As a result, the product's price in Germany will be reduced. Germany accounted for approximately 25% of Okedi® revenues, and the impact of this measure is expected to be concentrated primarily in the retail channel, which represented around 70% of Okedi® sales in that country in the first nine months of 2026. Sales of Neparvis®, a specialty product from Novartis, launched in Spain in December 2016, indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction, increased 3% to 43.3 million euros in the first nine months of 2026, compared to 42.1 million euros in the first nine months of 2025. The Neparvis® distribution agreement expired on October 16, 2026. However, ROVI and Novartis have entered into a new agreement to continue the commercialization of Neparvis® in Spain for a period of 5 years. Sales of Volutsa®, a specialty product from Astellas Pharma indicated for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia, launched in Spain in February 2015, decreased by 5% to 6.4 million euros in the first nine months of 2026, mainly due to the competitive environment following the entry of generics in the second quarter of 2023. Sales of Orvatez® , a specialty product from Organon & Co. (“Organon”) indicated as adjunctive therapy to diet in patients with hypercholesterolemia, decreased by 33% to 7.1 million euros in the first nine months of 2026, compared to the first nine months of 2025. This decrease was mostly caused by the entry of generics into the market, which resulted in a product price reduction by competitors. ROVI consequently dropped the price of Orvatez® by 40% in October 2024. CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS Sales of contrast imaging agents and other hospital products increased by 10% to 47.8 million euros in the first nine months of 2026. 11
Page 13
CDMO BUSINESS CDMO sales increased by 45% to 263.9 million euros in the first nine months of 2026 in comparison with the same period of 2025, mainly driven by: (i) the growth in business with existing customers following the restoration of full operational capacity at the Madrid facility after its temporary closure during the first half of 2025 to upgrade some Annex 1 GMP (Good Manufacturing Practices) aspects for aseptic manufacturing; and (ii) the contribution of revenue generated under the supply agreement with Bristol Myers Squibb entered into in connection with the acquisition of the Phoenix facility, completed on April 1, 2026. Over the past years, ROVI has developed a differentiated CDMO platform through investments in sterile fill & finish (F&F) capacity and technology services. With facilities in Spain and the United States, the Company continues to strengthen its global manufacturing network and expand its range of manufacturing services and capabilities. ROVI continues to identify business and partnership opportunities in high- growth segments, including innovative biologics, biotech products , vaccines and other specialised high value injectables in pre-filled syringes, vials and cartridges. OTHER INCOME Other income (grants) increased by 14.5 million euros to 23.6 million euros in the first nine months of 2026 compared with the same period of 2025. This increase mainly reflects the recognition of revenue related to the €36.3 million R&D aid awarded by the Technological Development and Innovation Centre (CDTI) for the LAISOLID project. The final decision published on 9 July 2025 confirmed the grant covering the period from January 2023 to August 2026. The full amount was received upon approval. Revenue is recognized as the related project expenses are incurred. As the grant period ended in August 2026, the grant was fully recognized by the end of the third quarter of 2026. COSTS GROSS PROFIT Gross profit increased 26% to 443.7 million euros in the first nine months of 2026. Gross margin showed an increase of 5.7 percentage points, from 67.1% in the first nine months of 2025 to 72.7% in the first nine months of 2026. This increase was impacted by the recognition of revenue associated with the R&D aid awarded by the CDTI for the LAISOLID project, which is recorded under the "Other income" line. E xcluding the impact of "Other income", gross margin would have increased by 3.5 percentage points to 68.9% mainly due to: (i) the increase in the CDMO business which contributed higher margins to Group sales, (ii) the increased contribution of Okedi® sales, which added high margins, and (iii) the decrease in LMWH raw material prices, which had a positive impact on gross margin. 12
Page 14
RESEARCH AND DEVELOPMENT EXPENSES R&D expenses increased by 136% to 58.4 million euros in the first nine months of 2026. They were mainly related to the preparation and start of the phase III clinical trial of Letrozole SIE2, with patient recruitment beginning in the third quarter of 2026. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES SG&A expenses increased 24% t o 221.2 million euros in the first nine months of 2026 compared with the first nine months of 2025. This increase was mainly driven by: • higher “Employee benefit expenses (excl. R&D),” which increased 25% year-on- year, driven primarily by (i) the addition of ROIS Phoenix Inc.'s employees following the company's inclusion in the Group's consolidation perimeter, (ii) a 3% wage increase due to the entry into force of the XXI Collective Agreement of the Chemical Industry 2024-20263, (iii) the hiring of new CDMO personnel, and (iv) the recognition of non-recurring expenses resulting mainly from the tax audit and investigation procedures carried out by the Tax and Customs Control Office of the Large Taxpayers Central Office regarding withholding taxes and advance tax payments on employment income, professional income and economic activities for the period between September 2020 and December 2022; and • higher “Other operating expenses (excl. R&D),” which increased 23% year-on year. This increase was mainly driven by (i) the incorporation of ROIS Phoenix Inc. into the Group's consolidation perimeter, (ii) lower operating expenses in the first nine months of 2025, a period during which they were reduced as a result of the temporary closure of the Madrid facility to upgrade some Annex 1 GMP aspects for aseptic manufacturing, and (iii) the recognition of non-recurring expenses mainly associated with the write-off of assets that are no longer operational and the execution of certain strategic projects. Expenses related to ROIS Phoenix Inc. represented approximately 12% of SG&A expenses in the first nine months of 2026. For 2026, ROVI maintains its guidance and expects SG&A expenses (excluding ROIS P h o e n i x I n c . f r o m t h e G r o u p ) t o i n c r e a s e b y a m i d - t o h i g h - s i n g l e ‑ d i g i t p e r c e n t a g e compared with 2025. SG&A expenses IN € MILLIONS 9M 2026 9M 2025 Growth % Growth Employee benefit expenses (excl. R&D) 121.2 96.8 24.4 25 % of which non-recurring expenses 1.6 — 1.6 n.a. Other operating expenses (excl. R&D) 100.0 81.2 18.8 23 % of which non-recurring expenses 3.4 2.8 0.6 22 % Total SG&A expenses 221.2 177.9 43.3 24 % 13 2 Superior Inhibition of Estrogens 3 Source: https://www.boe.es/eli/es/res/2025/02/06/(1)
Page 15
DEPRECIATION Depreciation and amortisation expenses increased by 25% to 27.9 million euros in the first nine months of 2026 compared to the same period of 2025, as a result of (i) the incorporation of ROIS Phoenix Inc. into the Group's consolidation perimete r, and (ii) the new property, plant and equipment and intangible asset purchases made during the last year. NET FINANCIAL COSTS Net financial costs decre ased by 1.2% to 1.9 million euros in the first nine months of 2026, compared with the first nine months of 2025. Net financial costs were mainly driven by higher finance costs as a result of late-payment interest associated with the tax audit covering fiscal years 2020 to 2022. This impact was partially offset by (i) gains arising from changes in the fair value of financial instruments , (ii) higher financial income in the first nine months of 2026 in comparison with the same period of 2025, and (iii) positive exchange differences. Excluding the financial costs associated with the tax audit, net financial result would have amounted to an expense of €0.5 million in the first nine months of 2026, reflecting a 73% improvement compared with the net financial expense recorded in the first nine months of 2025. EFFECTIVE TAX RATE The effective tax rate decreased by 4.7 percentage points from 22.0% in the first nine months of 2025 to 17.3% in the first nine months of 2026. This reduction was mainly attributable to the recognition of a gain on a bargain purchase (badwill) arising from the acquisition of the Phoenix facility, which was recorded as accounting income with no tax impact, thereby reducing the effective tax rate for the period. TAX AUDIT On 13 November 2024, Laboratorios Farmacéuticos Rovi, S.A. and Rovi Pharma Industrial Services, S.A. were notified of the commencement of audit and investigation procedures by the Large Taxpayers Central Office, Office of Tax and Customs Control in relation to the following items and periods: • Corporate income tax for the years 2020 to 2022. • Value-added tax from September 2020 to December 2022. • Withholdings/payments on account of earned income and income from professional and business activities from September 2020 to December 2022. • Withholdings on account of non-residents’ income tax from September 2020 to December 2022. As at 30 September 2026, the procedures for the years 2020-2022 had been concluded by the tax authorities and the relevant assessments were formally signed on 6 July 2026. No penalty proceedings arose from the procedures carried out by the audit team . The principal impacts on the Group’s financial statements are set out below: 14
Page 16
P&L impact Balance sheet impact MILLION € Non-current assets Current liabilities Selling, general and administrative expenses(1) 0.9 Finance costs 0.8 Income tax 0.1 Deferred tax assets 5.1 Trade and other payables 7.0 Total 1.9 5.1 7.0 (1) SG&A calculated as the amount of e mployee benefit expenses plus other operating expenses minus work carried out by the Group on non-current assets minus research & development expenses. The deferred tax asset recognised relates to the tax treatment of certain income and expenses related to the investments made to adapt the Group’s facilities for commercial manufacturing. As a result of a difference in criteria between the ROVI Group and the tax authorities regarding the tax accounting for certain assets acquired within the framework of these investments, an agreed settlement (“ acta con acuerdo ”) was signed, amending the tax bases for corporate income tax for the years 2020, 2021 and 2022. This amendment led to recognition of a deferred tax asset of 5.1 million euros, which is expected to be recovered in future years. Likewise, ROVI assessed the potential tax risks for the years 2023-2024 and, as a result of this assessment, recognised an expense of 1.1 million euros in profit or loss and a deferred tax asset of 8.1 million euros. Additionally, the Group revised the corporate income tax provision for 2025 resulting in recognition of a deferred tax asset for 1.0 million euros and a current tax liability for the same amount. FINANCIAL PERFORMANCE Million euros 97.7 91.6 (43.3) 62.4 (33.7) 0.1 (5.7) 0.02 (6.4) 162.8 Net profit 9M 2025(1) Gross profit(2) SG&A(3) Gain on bargain purchase R&D(4) Share of profit in associates and joint ventures DepreciationFinancial Result Income tax Net profit 9M 2026(1) (1)Net profit refers to the profit for the period. (2)Gross profit calculated as total revenue less change in inventories of finished goods and work in progress and raw materials and consumables used. (3)SG&A calculated as the amount of e mployee benefit expenses plus other operating expenses minus work carried out by the Group on non-current assets minus research & development expenses. (4)R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development. 15
Page 17
EBITDA EBITDA increased by 52% to 226.6 million euros in the first nine months of 2026, with an EBITDA margin of 37.1%, up 8.7 percentage points compared to the same period of 2025. This performance mainly reflects the impact of the gain on bargain purchase (badwill). EBITDA excluding badwill related to the acquisition of the Arizona facility, increased by 10% to 164.3 million euros in the first nine months of 2026, with EBITDA margin standing at 26.9%. EBIT EBIT increased by 56% compared to the first nine months of 2025, reaching 198.7 million euros in the first nine months of 2026. This performance resulted in an 8.3 percentage point improvement in EBIT margin, which stood at 32.6% in the first nine months of 2026, up from 24.2% in the first nine months of 2025. EBIT, excluding the aforementioned badwill, increased by 7% to 136.4 million euros in the first nine months of 2026, with EBIT margin standing at 22.4%. NET PROFIT Net profit amounted to 162.8 million euros in the first nine months of 2026, compared to 97.7 million euros in the same period of 2025, representing an increase of 67%. Non-controlling interests refer to ROVI's partners in Glicopepton Biotech, S. L. and Cells IA Technologies, S.L. PRE-R&D/FLAT R&D AND PRE-BADWILL EBITDA “Pre-R&D and Pre-Badwill” , calculated excluding badwill in the first nine months of 2026 and R&D expenses in the first nine months of 2026 and the first nine months of 2025, increased by 28%, from 174.2 million euros in the first nine months of 2025 to 222.7 million euros in the same period of 2026, reflecting a 3.3 percentage point increase in the EBITDA margin to 36.5% in the first nine months of 2026 (see “Pre-R&D costs and Pre-Badwill” columns of the table below). Likewise, recognizing the same amount of R&D expenses in the first nine months of 2026 as in the same period of 2025, EBITDA would have increased by 32% to 198.0 million euros, reflecting a 4.0 percentage point increase in the EBITDA margin to 32.4% in the first nine months of 2026, up from 28.5% in the same period of 2025 (see “Flat R&D costs and Pre-Badwill” columns of the table below). EBIT “Pre-R&D and Pre-Badwill”, calculated excluding badwill in the first nine months of 2026 and R&D expenses in the first nine months of 2026 and the first nine months of 2025, increased by 28%, from 152.0 million euros in the first nine months of 2025 to 194.8 million euros in the same period of 2026, reflecting a 3.0 percentage point increase in the EBIT margin to 31.9% in the first nine months of 2026 (see “Pre-R&D costs and Pre- Badwill” columns of the table below). Likewise, recognizing the same amount of R&D expenses in the first nine months of 2026 as in the first nine months of 2025, EBIT would have increased by 34% to 170.1 million euros, reflecting a 3.6 percentage point increase 16
Page 18
in the EBIT margin to 27.9% in the first nine months of 2026, up from 24.2% in the first nine months of 2025 (see “Flat R&D costs and Pre-Badwill” columns of the table below). Pre-R&D/Flat R&D and Pre-Badwill Reported Pre-R&D costs and Pre- Badwill Flat R&D costs and Pre- Badwill IN € MILLIONS 9M 2026 9M 2025 9M 2026 9M 2025 % Cto. 9M 2026 9M 2025 % Cto. Operating revenue(1) 610.2 525.1 610.2 525.1 16 % 610.2 525.1 16 % Other income(2) 23.6 9.0 23.6 9.0 n.a. 23.6 9.0 n.a. Total revenue(3) 633.7 534.1 633.7 534.1 19 % 633.7 534.1 19 % Cost of sales(4) (190.0) (182.0) (190.0) (182.0) 4 % (190.0) (182.0) 4 % Gross profit(5) 443.7 352.1 443.7 352.1 26 % 443.7 352.1 26 % % margin(11) 72.7 % 67.1 % 72.7 % 67.1 % 5.7 pp 72.7 % 67.1 % 5.7 pp R&D expenses(6) (58.4) (24.7) — — n.a. (24.7) (24.7) n.a. SG&A(7) (221.2) (177.9) (221.2) (177.9) 24 % (221.2) (177.9) 24 % Gain on bargain purchase 62.4 — — — n.a. — — n.a. Share of profit in associates and joint ventures 0.1 0.0 0.1 0.0 n.a. 0.1 0.0 n.a. EBITDA(8) 226.6 149.5 222.7 174.2 28 % 198.0 149.5 32 % % margin(11) 37.1 % 28.5 % 36.5 % 33.2 % 3.3 pp 32.4 % 28.5 % 4.0 pp EBIT(9) 198.7 127.3 194.8 152.0 28 % 170.1 127.3 34 % % margin(11) 32.6 % 24.2 % 31.9 % 28.9 % 3.0 pp 27.9 % 24.2 % 3.6 pp (1) Operating revenue refers to revenue. (2) Other income includes the recognition of government grants on non-financial non-current assets and other. (3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other. (4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use. (5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used. (6) R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development. (7) SG&A calculated as the amount of e mployee benefit expenses plus other operating expenses minus work carried out by the Group on non-current assets minus research & development expenses. (8) EBITDA calculated as profit before interest, taxes, depreciation and amortization. (9) EBIT calculated as profit before taxes and interest. (10) Net profit refers to profit for the period. (11) The gross margin and the EBITDA, EBIT and net profit margins are calculated as the result of dividing the gross profit, the EBITDA, the EBIT and the net profit, respectively, by revenue, expressed as a percentage. DIVIDEND ROVI's General Shareholders Meeting, held on 17 June 2026, approved the payment of a dividend equivalent to 0.9594 euros per share entitled to receive it, charged to the 2025 profit and distributable reserves. This would entail distribution to an amount equivalent to approximately 35% of the consolidated net profit for 2025 attributed to the parent company. This dividend was paid on 15 July 2026. 17
Page 19
FINANCIAL POSITION Balance Sheet IN € MILLIONS September 30, 2026 December 31, 2025 Growth % Growth Assets Non-current assets 568.5 389.0 179.6 46 % Current assets 568.2 566.7 1.5 0 % Total assets 1,136.8 955.7 181.1 19 % Equity 798.4 675.5 123.0 18 % Liabilities Non-current liabilities 126.4 99.0 27.3 28 % Financial debt 73.9 93.2 (19.3) -21 % Current liabilities 212.0 181.2 30.8 17 % Financial debt 27.1 28.6 (1.6) -5 % Total liabilities 338.4 280.2 58.1 21 % Total equity and liabilities 1,136.8 955.7 181.1 19 % TOTAL ASSETS ROVI’s total assets increased 19%, from 955.7 million euros as of December 31, 2025 to 1,136.8 million euros as of September 30, 2026, mainly because of (i) an increase of 165.5 million euros in "Property, Plant and equipment" as a result of the incorporation of ROIS Phoenix Inc. in the Group's consolidation perimeter, (ii) an increase of 70.0 million euros in "Trade and accounts receivables" mainly related to the billing linked to CDMO partners, and (iii) an increase of 14.2 million euros in "Deferred income tax assets", mainly related to the agreement reached between the ROVI Group and the Spanish Tax Agency regarding the amendment of the taxable bases for fiscal years 2020, 2021 and 2022 in the context of the corporate income tax audit . These increases were partially offset by a (i) decrease of 43.4 million euros in "Inventories"; and (ii) a decrease of 27.1 million euros in "Cash and cash equivalents". EQUITY ROVI’s equity increased by 18% to 798.4 million euros as of September 30, 2026, mainly as a result of the increase in profit for the period. TOTAL LIABILITIES ROVI’s total liabilities increased by 21% from 280.2 million euros as of 31 December, 2025 to 338.4 million euros as of 30 September, 2026. This increase was mainly due to (i) an increase of 51.7 million euros in "Contract liabilities," (ii) an increase of 21.4 million euros in "Deferred income tax liabilities ", both resulting from the incorporation of ROIS Phoenix 18
Page 20
Inc. in the Group's consolidation perimeter; and (iii) an increase of 27.4 million euros in “Current income tax liabilities". These increases were partially offset by (i) a decrease of 23.2 million euros in “Deferred income”; and (ii) a 20.9 million euro decrease in “Financial debt.” As of 30 September, 2026, ROVI total debt decreased to 100.9 million euros. Total Debt IN € THOUSANDS September 30, 2026 December 31, 2025 Interest rate Bank borrowings 79,814 94,994 0.68-3.00 Debt with public administration 10,009 11,043 — Financial liabilities for leases 11,123 15,687 — Derivative financial instruments — 97 — Total 100,946 121,821 As of 30 September, 2026, bank borrowings decreased by 15.2 million euros. Bank borrowings are composed of the loans set out in the following table: Instrument Opening balance (€m) Outstanding balance (€m) Maturity Interest rate Current rate Loan BEI 2017 45.0 20.0 (i) Variable tranche 5.0 1.4 2028 Euribor 3M + 0.844% 3.157% (ii) Fixed tranche 40.0 18.6 2029 0.681% 0.681% Loan BEI 2024* 10.0 10.0 2034 Euribor 3M + 0.655% 3.148% Bank loan 2024 25.0 14.2 2029 3.0% fixed 3.000% Bank loan 2025 46.5 35.5 2030 2.75% fixed 2.750% Note: Bank borrowings are amortised on a quarterly basis. "€m": millions of euros *Although the amount granted was 50 million euros, only 10 million euros was drawn in July 2024. As the maturity of the loan is 10 years from drawdown, the maturity date of this tranche is July 2034. No further funds will be drawn under this facility, as the period available for new drawdowns expired in July 2024. Additionally, ROVI holds three credit facilities for 20 million euros each. No drawdowns had been made against any of them as of 30 September 2026. Instrument Opening balance (€m) Outstanding balance (€m) Maturity Interest rate Credit facility 20.0 Not drawn 2026 Euribor 3M + 0.50%20.0 Not drawn 2027 20.0 Not drawn 2027 "€m": millions of euros 19
Page 21
GROSS CASH POSITION AND NET DEBT (-)/CASH (+) As of 30 September, 2026, ROVI had a gross cash position of 73.1 million euros, compared to 99.9 million euros a s of 31 December, 2025, and net debt of 27.9 million euros, compared to net debt of 21.9 million euros as of 31 December, 2025. Gross cash position and net debt (-)/cash (+) IN € MILLIONS September 30, 2026 December 31, 2025 Deposits 2.2 1.9 Cash and cash equivalents 70.9 98.0 Gross cash position 73.1 99.9 Financial debt (100.9) (121.8) Net debt/cash (27.9) (21.9) Net cash generated in operating activities amounted to 111.0 million euros in the first nine months of 2026, compared to 101.4 million euros in the first nine months of 2025. Million euros (21.9) 111.0 (50.3) (23.0) (49.1) (0.5) 5.8 (27.9) Net debt (-)/ cash (+) FY 2025(1) Net cash from operating activities Capex Other cash flows from investing activities Dividends paid Treasury Shares Other Net debt (-)/ cash (+) 9M 2026(1) (1) Net debt (-) /cash (+) is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt. 20
Page 22
LIQUIDITY Cash Flow IN € MILLIONS 9M 2026 9M 2025 Growth % Growth Cash flow from operating activities 111.0 101.4 9.6 10 % Cash flow from investing activities (73.3) (39.4) (33.8) 86 % Cash flow from financing activities (64.9) (39.9) (25.0) 63 % Exchange rate differences 0.04 — 0.04 n.a. Net increase/ (decrease) in cash (27.1) 22.1 (49.1) n.a. Cash at the beginning of the year 98.0 27.2 70.8 n.a. Cash at the end of the period 70.9 49.3 21.7 44 % Note: the amount reported in the first nine months of 2025 as "Cash due to change in consolidation perimeter" has been reclassified and is presented in the first nine months of 2026 press release under "Cash flow from investing activities." CASH FLOW FROM OPERATING ACTIVITIES Cash flow from operating activities increased to 111.0 million euros in the first nine months of 2026 from 101.4 million euros in the same period of 2025. This increase was mainly due to: • the increase of 42.9 million euros in "Inventories" item in the first nine months of 2026, compared to an increase of 19.5 million euros in the same period of 2025; • the increase of 15.5 million euros in "Cash flow from contract manufacturing services" item in the first nine months of 2026, compared to a decrease of 17.0 million euros in the first nine months of 2025; and • the decrease of 7.3 million euros in "Trade and other payables" item in the first nine months of 2026, compared to a decrease of 24.0 million euros in the first nine months of 2025. These effects were partially offset by: • the decrease of the "Trade and other receivables" item, which amounted to 69.4 million euros in the first nine months of 2026, compared to a decrease of 43.7 million euros in the same period of 2025; and • the absence of "Proceeds from grants" in the first nine months of 2026, compared to an increase of 40.1 million euros in the same period of 2025. 21
Page 23
CASH FLOW FROM INVESTING ACTIVITIES ROVI invested 50.3 million euros in the first nine months of 2026, compared to 38.5 million euros in the first nine months of 2025. Purchases of property, plant and equipment and intangible assets ("Capex") IN € MILLIONS 9M 2026 9M 2025 Growth % Growth Madrid Injectable plant 3.3 1.6 1.7 n.a. San Sebastián de los Reyes plant 4.6 2.6 2.0 n.a. Granada plant 0.1 0.3 (0.2) -63 % Alcalá de Henares plant 3.1 4.2 (1.1) -26 % Escúzar plant 0.2 2.8 (2.6) -93 % Expenditure on maintenance and other capex 2.9 1.4 1.5 102 % Maintenance Capex 14.3 13.0 1.3 10 % ISM industrialisation 0.6 0.9 (0.3) n.a. Glicopepton 11.5 6.8 4.6 n.a. New filling lines and operations expansion 24.1 17.8 6.3 35 % Investment Capex 36.1 25.5 10.6 42 % Total Capex 50.3 38.5 11.9 31 % Notes: Capex related to the Phoenix facility has been included within "New filling lines and operations expansion". Capex figures for the first nine months of 2025 have been reclassified between certain line items compared with the information published in the first nine months 2025 results release, with no impact on the total amount. FREE CASH FLOW Free cash flow decreased to 61.9 million euros in the first nine months of 2026 from 63.3 million euros in the same period of 2025. Free cash flow IN € MILLIONS 9M 2026 9M 2025 Net cash generated from (used in) operating activities 111.0 101.4 Acquisitions of intangible assets (2.5) (1.3) Acquisitions of property, plant and equipment (47.9) (37.2) Proceeds from sale of property, plant and equipment — 0.1 Interest received 1.2 0.3 Free cash flow 61.9 63.3 22
Page 24
CASH FLOW FROM FINANCING ACTIVITIES Cash flow from financing activities was (64.9) million euros in the first nine months of 2026 versus (39.9) million euros in the same period of 2025. This variation was mainly driven by (i) lower financing received in the first nine months of 2026, which amounted to 0.3 million euros , in comparison with 47.6 million euros received in the first nine months of 2025, and (ii) higher cash outflows related to treasury share purchases, which totalled 55.4 million euros, compared with 44.8 million euros in the same period of the previous year. These effects were partially offset by (i) lower cash outflows related to the repayment of financial debt, which amounted to 21.5 million euros in comparison with 39.4 million euros in the first nine months of 2025, and (ii) higher proceeds from the reissuance of treasury shares to third parties, which increased to 55.0 million euros in the first nine months of 2026 from 44.8 million euros in the first nine months of 2025. Javier López-Belmonte Encina, Deputy Chairman and Chief Financial Officer of ROVI, said: "Our results for the first nine months of 2026 reflect the strength and diversification of ROVI’s business model. Operating revenue increased by 16% to 610.2 million euros, driven by the strong performance of our Contract Development and Manufacturing Organization (CDMO) business and the continued growth of Okedi® (Risperidone ISM®). Gross profit rose by 26%, while gross margin improved by 5.7 percentage points to 72.7%, supported by the favourable performance of the CDMO business, the growing contribution from Risperidone ISM®, lower LMWH raw material prices, and the recognition of income associated with the R&D grant awarded by the CDTI for the LAISOLID project. Reported EBITDA increased by 52% to 226.6 million euros, mainly reflecting the impact of the badwill arising from the acquisition of the Phoenix manufacturing facility in Arizona, U.S. Excluding this effect, EBITDA increased by 10% to 164.3 million euros compared with the first nine months of 2025, demonstrating the underlying strength of the business despite our significant investment in R&D, which reached 58.4 million euros. In light of the strong performance achieved during the first nine months of the year and the visibility we have for the remainder of 2026, we have upgraded our guidance and now expect operating revenue to grow in the mid- to high-single-digit range compared with 2025, mainly driven by the strong momentum of our CDMO business and higher expected volumes from our bemiparin partners”. 23
Page 25
R&D UPDATE ISM® technology platform ROVI is developing Letrozole SIE (Superior Inhibition of Estrogens) (formerly Letrozole LEBE) for the treatment of hormone receptor-positive breast cancer. This investigational medicine is expected to be superior to the oral letrozole (Femara® 4) marketed currently due to its increased oestrogen suppression which is expected to result in clinical benefits. Accordingly, its clinical development plan includes an efficacy trial in postmenopausal women with advanced breast cancer designed to demonstrate the superior efficacy of Letrozole SIE versus Femara® in delaying disease progression (SIE-35). This new investigational medicine is planned to follow the regulatory pathway 505(b)(2) in the United States and a hybrid application (under Article 10(3) of Directive 2001/83/EC) will be filed in Europe, seeking marketing authorisation with the same therapeutic indications as Femara® in both the United States and Europe. This would allow Letrozole SIE to be used at all the stages of breast cancer in postmenopausal women with oestrogen receptor-positive tumours. A single-dose phase I study (LEILA-1)6 conducted in Europe has recently finished. The final results support the progression to the next steps of the clinical develop programme. Consequently, the Investigational New Drug (IND) Application of Letrozole SIE has already been reviewed by the US Food and Drug Administration (FDA). Patient recruitment in the following clinical trials, including a Phase III efficacy trial, commenced during the third quarter of 2026. Furthermore, ROVI is also developing Risperidone QUAR, a quarterly long-acting risperidone injection. The first phase I clinical trial with ascending doses 7 has already finished and final data confirm that this formulation, similarly to Okedi®, is able to provide plasma levels in the therapeutic range on the same day as the injection without the need for prior injections of monthly formulations, loading doses or concomitant oral risperidone doses. Consequently, ROVI is currently starting up two new multinational clinical studies, including a phase III efficacy trial. Patient enrollment is planned to begin by the fourth quarter of 2026. Most patients suffering from schizophrenia have a lack of insight into their disease, resulting in lack of adherence. Risperidone QUAR will allow patients who are admitted to hospital because their condition is deteriorating to be treated with a single injection covering the three most important months, from the early moments of the episode to the stabilisation of the patient. 24 4 Femara® is a registered trademark of Novartis AG 5 A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3). National Library of Medicine. Clinicaltrials.gov. NCT07340658 (available at: https://clinicaltrials.gov/study/NCT07340658). 6 Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women (LEILA-1). National Library of Medicine. Clinicaltrials.gov. NCT06315205 (available from: https://clinicaltrials.gov/study/NCT06315205 7 Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (QUARTZ). National Library of Medicine. Clinicaltrials.gov. NCT06276361 (available from: https://clinicaltrials.gov/study/NCT06276361).
Page 26
ROVI plans to register this new medicine in the European Union through a hybrid application (under Article 10(3) of Directive 2001/83/EC), for which it has designed a clinical programme similar to the one previously executed for Okedi®, with the objective of obtaining the same therapeutic indication as the latter: treatment of schizophrenia in adults for whom tolerability and effectiveness have been established with oral risperidone. ESG ROVI has been included in the IBEX ESG Index, managed by Bolsas y Mercados Españoles (BME), for the fourth consecutive year. The index comprises 48 companies that are members of either the IBEX 35 or the IBEX Medium Cap indices. This index recognises the listed companies with the best environmental, social and governance (ESG) performances. Inclusion on the IBEX ESG reinforces ROVI’s commitment to decarbonisation and the creation of sustainable value for all its stakeholders. In December 2025, ROVI’s Board of Directors approved a new five-year Master Plan (2026-2030), structured around three core concepts through 25 KPIs which, if they are fulfilled, will guide the transformation towards a more responsible and sustainable business model. The Group’s priority focus is on the following three strategic pillars: • Environmental protection: focused on climate change mitigation, promoting the circular economy, and efficient and responsible resources management. • Social management: ROVI devotes its efforts to managing talent and reinforcing the corporate culture as well as promoting employee well-being, ensuring safety in the operations and creating a positive social impact. • Responsible governance: the company emphasises its culture of integrity, extends its standards of ethics and environmental protection to its value chain and integrates sustainability into the decision-making of the chief governance bodies. Additionally, ROVI, as a member of the United Nations Global Compact supports, by adopting and disseminating them, the integration of the principles of said Compact and other international instruments, especially in the areas of human rights, workplace practices, the environment and the fight against corruption. About the LAISOLID Project Laboratorios Farmacéuticos ROVI is developing LAISOLID, a strategic research and development project funded by the Centre for the Development of Technology and Innovation (CDTI) under the Recovery, Transformation and Resilience Plan, financed by the European Union through NextGenerationEU. LAISOLID is an R&D initiative aimed at developing aseptic filling technologies for complex polymeric matrices capable of containing cells and biological materials for 25
Page 27
regenerative medicine therapies, as well as incorporating active pharmaceutical ingredients with applications in tissue regeneration and in the development of pharmacological treatments designed to improve efficacy in the treatment of serious diseases such as breast cancer. About ROVI ROVI is an international pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The Company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Austria and maintains a diversified marketing portfolio of more than 40 products, among which its flagship product, bemiparin, also present in more than 60 countries all over the world, should be highlighted. Likewise, ROVI markets its enoxaparin biosimilar, developed in-house, in Europe and it is also present in approximately 60 countries. ROVI continues to drive the development the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release that has given rise to, among other innovations, Risperidone ISM® to treat schizophrenia in adults. For further information, please visit www.rovi.es. For further enquiries, please contact: Juan López-Belmonte Encina Chairman and Chief Executive Officer www.rovi.es Javier López-Belmonte Encina Deputy Chairman and Chief Financial Officer www.rovi.es Marta Campos Martínez Head of Finance +34 912444422 mcampos@rovi.es www.rovi.es Beatriz de Zavala Mazarredo Investor Relations Analyst +34 610 737 703 bdezavala@rovi.es www.rovi.es Victoria López-Belmonte Tabuyo Investor Relations Analyst +34 680 669 485 vlopez-belmonte@rovi.es www.rovi.es 26
Page 28
Forward-looking statements This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date after the date of this press release. 27
Page 29
APPENDIX 1 LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2026 AND DECEMBER 31, 2025 IN € THOUSANDS* September 30, 2026 December 31, 2025 ASSETS Non-current assets Property, plant and equipment 496,251 330,735 Goodwill 2,702 2,702 Intangible assets 32,895 33,183 Investments in joint ventures and associated companies 19,311 19,164 Deferred income tax asset 17,382 3,199 568,541 388,983 Current assets Inventories 244,585 287,975 Trade and other receivables 247,581 177,540 Current income tax assets 111 29 Prepaid expenses 5,056 3,188 Cash and cash equivalents 70,916 97,976 568,249 566,708 Total assets 1,136,790 955,691 *The figures as of September 30, 2026 have not been audited. The figures as of December 31, 2025 are audited figures. 28
Page 30
LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2026 AND DECEMBER 31, 2025 IN € THOUSANDS* September 30, 2026 December 31, 2025 EQUITY Equity attributed to parent company 779,788 664,415 Share capital 3,074 3,074 Share premium 87,636 87,636 Legal reserve 673 673 Treasury shares (5,474) (5,174) Retained earnings and voluntary reserves 528,678 437,818 Profit for the period 162,892 140,442 Accumulated other comprehensive income 2,309 (54) Non-controlling interests 18,624 11,040 Total equity 798,412 675,455 LIABILITIES Non-current liabilities Financial debt 73,886 93,204 Deferred income tax liabilities 21,574 160 Other non-current payables 195 191 Contract liabilities 27,771 2,016 Deferred income 2,930 3,443 126,356 99,014 Current liabilities Financial debt 27,060 28,617 Trade and other payables 120,284 118,559 Current income tax liabilities 31,757 4,402 Contract liabilities 29,980 4,042 Deferred income 2,941 25,602 212,022 181,222 Total liabilities 338,378 280,236 Total equity and liabilities 1,136,790 955,691 *The figures as of September 30, 2026 have not been audited. The figures as of December 31, 2025 are audited figures. 29
Page 31
LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS FOR THE NINE-MONTH PERIODS ENDING SEPTEMBER 30, 2026 AND SEPTEMBER 30, 2025 IN € THOUSANDS* 9M 2026 9M 2025 Revenue 610,170 525,063 Changes in inventories of finished goods and work in progress (33,254) (4,218) Raw materials and consumables used (156,753) (177,741) Employee benefit expenses (129,702) (105,075) Other operating expenses (150,491) (97,990) Work carried out by the Group on non-current assets 590 392 Amortisation and depreciation (27,882) (22,217) Recognition of government grants on non- financial non-current assets and other 23,571 9,039 Gain on bargain purchase 62,352 — Share of profit in joint ventures and associated companies 147 8 OPERATING PROFIT (EBIT) 198,748 127,261 Finance income 1,200 793 Finance costs (3,381) (2,085) Impairment and gain or loss on measurement of financial instruments 116 (505) Exchange difference 150 (142) FINANCE INCOME/(COSTS) - NET (1,915) (1,939) PROFIT BEFORE INCOME TAX 196,833 125,322 Income tax (34,052) (27,611) PROFIT FOR THE PERIOD 162,781 97,711 Profit for the period attributable to parent company 162,892 97,765 Profit attributable to non-controlling interests (111) (54) *Unaudited figures. 30
Page 32
LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED CASH FLOW STATEMENTS FOR THE NINE-MONTH PERIODS ENDING SEPTEMBER 30, 2026 AND SEPTEMBER 30, 2025 IN € THOUSANDS* 9M 2026 9M 2025 Cash flows from operating activities Profit before income tax 196,833 125,322 Adjustments for non-monetary transactions: Amortisation and depreciation 27,882 22,217 Finance income (1,200) (793) Loss allowance 2,332 (4,553) Adjustments for changes in value of derivatives (97) — Gain or loss on derecognitions of financial assets and liabilities (19) 505 Finance expenses 3,381 2,085 Exchange rate differences (150) 142 Gain on bargain purchase (62,352) — Grants, distribution licenses and other deferred income (23,916) (9,428) Gain or loss on disposal of fixed assets 1,766 — Share in profit/(loss) of joint ventures and associated companies (147) (8) Changes in working capital: Trade and other receivables (69,388) (43,732) Inventories 42,949 19,534 Other current assets (prepaid expenses) (1,397) (958) Trade and other payables (7,256) (23,995) Other collections and payments: Cash flow from contract manufacturing services 15,465 (16,976) Proceeds from distribution licenses 5 480 Proceeds from grants — 40,105 Cash flow from taxes (13,654) (8,550) Net cash generated from (used in) operating activities 111,037 101,397 Cash flows from investing activities Acquisitions of intangible assets (2,450) (1,310) Acquisitions of property, plant and equipment (not including rights of use) (47,877) (37,150) Proceeds from sale of property, plant and equipment — 85 Other cash flows from investing activities (22,951) (3,138) Other amounts received or paid — 2,064 Net cash flows generated from (used in) investing activities (73,278) (39,449) Cash flows from financing activities Repayments of financial debt (21,520) (39,432) Proceeds from financial debt 274 47,611 Interest paid (1,777) (1,723) Purchase of treasury shares (55,448) (44,768) Reissue of treasury shares 54,986 44,750 Capital contribution in subsidiaries 7,695 1,508 Net cash flows generated from (used in) financing activities (64,857) (39,884) Exchange rate differences 38 — Net (decrease) increase in cash and cash equivalents (27,060) 22,064 Cash & cash equivalents at beginning of the period 97,976 27,186 Cash and cash equivalents at end of the period 70,916 49,250 *Unaudited figures. 31
Page 33
APPENDIX 2 ALTERNATIVE PERFORMANCE MEASURES In addition to the financial information prepared in accordance with International Financial Reporting Standards (“IFRSs”) taken from our financial statements, this document includes certain alternative performance measures (“APMs”) as defined in the ESMA (European Securities and Markets Authority) Guidelines on Alternative Performance Measures of 5 October, 2015 (ESMA/2015/1415), as well as some non-IFRS financial indicators. The financial measures contained in this document that are considered APMs or non-IFRS financial indicators have been prepared on the basis of the ROVI Group’s financial information but are not defined or set out in detail within the framework of the applicable financial information and have not been audited or reviewed by ROVI's auditors. These APMs are considered figures that have been adjusted in respect of those that are presented in accordance with the International Financial Reporting Standards endorsed by the European Union (IFRS-EU), which form the applicable accounting framework for the consolidated financial statements of the ROVI Group. Therefore, the reader should consider them to complement the latter but not to replace them. ROVI uses these APMs and non-IFRS financial indicators to plan, oversee and assess its performance. ROVI considers the APMs and non-IFRS financial indicators to be useful to allow the management team and investors to compare the past or future financial performance, the financial situation and the cash flows. Notwithstanding, these APMs and non-IFRS financial indicators are considered complementary and are not intended to replace IFRS measures. Furthermore, other companies, including some in ROVI's sector, may calculate such measures differently, which reduces their usefulness for comparative purposes. This document contains information on the alternative performance measures (APMs) and non-IFRS financial indicators used by ROVI, including their definitions and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs. The document is available on ROVI's website and may be accessed on the following link: (https://www.rovi.es/en/shareholders-investors/financial-business-information). In this respect, in accordance with the Guidelines issued by the European Securities and Markets Authority (ESMA), in force since 3 July, 2016, in relation to the transparency of Alternative Performance Measures, ROVI provides below information concerning the APMs it considers significant that are included in this press release: • Operating revenue This APM shows the revenue that the group generates from its main business activities. Operating revenue refers to revenue. 32
Page 34
• Other income Other income shows the grants obtained by the Group to develop its R&D&I and other projects. Other income refers to the recognition of government grants on non-financial non- current assets and other. • Total revenue This APM shows all the group’s revenues. We calculate total revenue as revenue plus the recognition of government grants on non-financial non-current assets and other. • Cost of sales The cost of sales reflects the cost involved in producing or acquiring the products or services that ROVI sells. The cost of sales is calculated as the amount of raw materials and consumables used plus that corresponding to the changes in inventories of finished goods and work in progress. • Gross profit Gross profit is an indicator that measures the direct profit that ROVI obtains from carrying out its income-generating activities. We calculate gross profit as total revenue less cost of sales. • Gross margin or gross profit as % of operating revenue This APM is a percentage indicator that measures the direct profit that ROVI obtains from its operating revenue. We calculate gross margin or gross profit as % of operating revenue as the percentage that the gross profit represents in the revenue (operating revenue). • Research & Development ("R&D") Expenses R&D expenses reflect expenses related to scientific research and technological development carried out by ROVI. R&D expenses are calculated as the sum of employee benefits expenses and other operating expenses related to scientific research and technological development. • SG&A Expenses Selling, General & Administrative (SG&A) Expenses is an indicator that measures expenses related to the general internal operations and management of the company. SG&A calculated as the amount of employee benefit expenses plus other operating expenses minus work carried out by the Group on non-current assets minus research & development expenses. 33
Page 35
• EBITDA EBITDA (Earnings Before Interest, Tax, Depreciation and Amortization) is an indicator that measures the group’s operating profit before interest, taxes, impairment, depreciation and amortization have been deducted. Management uses it to assess the results over time, allowing a comparison with other companies in the sector. We calculate EBITDA as profit before: taxes, interest, depreciation and amortization. • EBITDA margin or EBITDA as % of operating revenue This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest, taxes, impairment, depreciation and amortization are deducted. We calculate EBITDA margin or EBITDA as % of operating revenue as the percentage that the EBITDA represents in the revenue (operating revenue). • EBITDA “Pre-R&D and Pre-Badwill” This APM is used by ROVI to show EBITDA from the on-going business. We calculate EBITDA “Pre-R&D and Pre-Badwill” as EBITDA excluding: R&D expenses and badwill. • EBIT EBIT (Earnings Before Interest and Taxes) is an indicator that measures the group’s operating profit before interest and tax are deducted. Like EBITDA, Management uses it to assess the results over time, allowing a comparison with other companies in the sector. We calculate EBIT as profit before: taxes and interest. • EBIT margin or EBIT as % of operating revenue This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest and tax are deducted. We calculate EBIT margin or EBIT as % of operating revenue as the percentage that the EBIT represents in the revenue (operating revenue). • EBIT “Pre-R&D and Pre-Badwill” This APM is used by ROVI to show EBIT from the on-going business. We calculate EBIT “Pre-R&D and Pre-Badwill” as operating profit for the period excluding: R&D expenses and badwill. • Net profit Net profit is an indicator that measures the group´s profit for the period. We calculate Net profit as EBIT plus finance costs-net and income tax. 34
Page 36
• Net profit as % of operating revenue This APM is a percentage indicator that measures the profit for the period that ROVI obtains from its operating revenue. We calculate net profit as % of operating revenue as the percentage that the net profit represents in the revenue (operating revenue). • Gross cash position Gross cash position is an indicator that measures the amount of cash the group has at a specific point in time. We calculate gross cash position as equity securities plus deposits plus financial derivatives plus financial assets at amortised cost plus cash and cash equivalents. • Net debt (-)/cash (+) Net cash, also measured as financial debt or net debt, is the main indicator used by Management to measure the group’s indebtedness. It is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt. • Capex Capex is an indicator used to better understand the investments made by the group in its operations. We calculate Capex as purchases of property, plant and equipment and intangible assets. • Capex as % of operating revenue This APM is a percentage indicator that measures the group's investments in property, plant and equipment, and intangible assets to its operating revenues. We calculate Capex as % of operating revenue as the percentage that the purchases of property, plant and equipment and intangible assets represents in the revenue (operating revenue). • Free Cash Flow (FCF) Free cash flow is an indicator that measures cash flow generation from operating and investment activities and is useful for evaluating the funds available for paying shareholder dividends and servicing debt. We calculate free cash flow as net cash generated from or used in operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment and intangible assets plus interest received. 35
Page 37
• FCF as % of operating revenue This APM is a percentage indicator that measures the group's cash flow generation from operating and investment activities relative to its operating revenues. We calculate FCF as % of operating revenue as the percentage that the free cash flow represents in the revenue (operating revenue). 36